Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:1346 (4 December), doi:10.1136/bmj.329.7478.1346
| The first 150 words of the full text of this article appear below. |
EDITORSenn questions whether individual response to treatment is a valid assumption.1 Patients have never responded consistently to treatment, and, additionally, every time a prescription is written (except for identical twins) what effectively begins is a clinical trial with n = 1.
Evidence based medicine or evidence based clinical practice is the judicious application of best current knowledge to the condition and values of each patient.2 It should therefore allow for individualised treatment, which may entail a drug different from the "best" identified after systematic review. Can the gold standard randomised controlled trial really deliver the desired certainty when identifying which patients will respond to the treatment is impossible?
Trials organised by pharmaceutical companies are designed to show the superiority of a company's product over a competitor's to ensure optimum market share, with little thought for the individual patient receiving the drug. Promotion follows to ensure product recognition at
Alfred P J Lake, consultant in anaesthesia and pain management
Glan Clwyd Hospital, Rhyl, Clwyd LL18 5UJ apjlake@aol.com